Genetic testing to distinguish X-linked protoporphyria from erythropoietic protoporphyria informed iron replacement therapy leading to reversal of severe protoporphyric hepatopathy Authors: Christopher D. Ma, Giuliana Arevalo, Siobán B. Keel, Cynthia Levy Published: 2026 ABSTRACT Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are cutaneous porphyrias characterized by excess protoporphyrin IX (PPIX), leading to photosensitivity and, in a minority of patients, progressive hepatobiliary injury. Although XLP and EPP have similar clinical presentations and management, they differ in their response to iron repletion. A reduction in PPIX levels has been demonstrated in XLP, whereas this effect has not been consistently observed in EPP. Data on the role of iron supplementation in XLP-associated liver dysfunction are limited to a single pediatric case report and a pilot study that included only two adult patients with XLP. Here, we describe a 64-year-old man with a history of presumed EPP who underwent liver transplantation for decompensated cirrhosis attributed to protoporphyric hepatopathy and possible alcohol-related disease, who presented with recurrence of hepatopathy and photosensitivity. Serial erythrocyte PPIX levels increased from 3250 to 4368 and then to 5561 μg/dL with multiple liver biopsies confirming marked porphyrin deposition without rejection. During evaluation for bone marrow transplant, genetic testing revealed a pathogenic ALAS2 variant, confirming XLP. Oral iron replacement was started after the diagnosis of iron deficiency anemia. Although the underlying cause of iron deficiency was not fully investigated, given the urgent need to address the XLP-related symptoms, iron supplementation was initiated and resulted in rapid improvement in photosensitivity and liver chemistries. This was accompanied by a marked reduction in erythrocyte PPIX levels to 1940 μg/dL. This case demonstrates the importance of genetic testing, as iron repletion may serve as a disease-modifying therapy for XLP-associated hepatopathy, even after liver transplantation. Introduction Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are erythropoietic cutaneous porphyrias characterized by excess accumulation of protoporphyrin IX (PPIX), predominantly in developing red cell precursors in the bone marrow. Unlike the blistering cutaneous porphyrias (e.g., porphyria cutanea tarda and congenital erythropoietic porphyria), in which porphyrin accumulation in the skin causes fragility and bullae, EPP and XLP are non-blistering cutaneous porphyrias in which excess PPIX causes acute, painful phototoxicity without skin fragility or scarring. PPIX then enters the circulation, where it leads to painful photosensitivity, and is taken up by the liver. In a minority of patients, this hepatic accumulation results in progressive hepatobiliary injury [1], [2], [3], [4]. Although both disorders present similarly, EPP is caused by loss-of-function mutations in FECH, whereas XLP results from gain-of-function mutations in ALAS2; both lead to excess accumulation of PPIX within erythrocytes, plasma, skin, and the liver (Table 1) [4], [5]. Liver involvement is more common in XLP than EPP, and can range from mild biochemical abnormalities to progressive cholestatic injury, fibrosis, cirrhosis, and rarely, liver failure requiring transplantation [5], [6]. Management focuses on minimizing hepatic insults, including alcohol and hepatotoxic medications, and preventing viral hepatitis through hepatitis A and B vaccination [5], [6], [7], [8]. Additional approaches may include ursodeoxycholic acid to enhance biliary porphyrin clearance, bile acid sequestrants (cholestyramine or colestipol) to reduce enterohepatic recirculation of PPIX, and, in severe cases, plasmapheresis, red-cell exchange or transfusion, intravenous hemin, and liver transplantation (LT) [3], [5], [8], [9], [10]. Although LT can be life-saving in advanced disease, it does not correct the underlying erythropoietic defect; therefore, patients may benefit from subsequent bone marrow transplantation to prevent recurrence [11], [12], [13]. The role of iron has been controversial in EPP, but it has shown benefit in a few reports in XLP [7], [14], [15], [16]. We present a patient with recurrent protoporphyric hepatopathy and photosensitivity 1.5 years after LT from initially presumed EPP, later confirmed to have XLP, who had rapid biochemical and clinical remission shortly after initiation of oral iron supplementation.Table 1Comparison of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Clinical features and management.DomainEPPXLPGenetic basisAutosomal recessive or biallelic FECH deficiencyX-linked gain-of-function variants in ALAS2PathophysiologyReduced ferrochelatase activity → impaired insertion of iron into PPIX → accumulation of free PPIXIncreased ALAS2 activity → overproduction of PPIX despite normal ferrochelatase functionAge of onsetUsually childhoodChildhood or adulthood; sometimes later recognitionPhotosensitivityCommon; immediate burning, erythema, and pain after minimal sunlight exposureClinically similar to EPP; often indistinguishable based on symptoms aloneHematologic profileIron deficiency frequent; ferritin often low or low-normalIron deficiency also common; may be more pronouncedLiver involvementRisk of hepatic PPIX deposition leading to cholestasis and hepatopathy; may progress to liver failure in severe casesAt risk for hepatopathy; severity can mirror EPP, but some cases may progress more rapidly due to higher PPIX levelsDiagnostic cluesElevated erythrocyte PPIX with high free-to‑zinc PPIX ratio; FECH gene testing confirmsElevated erythrocyte PPIX with proportionally higher zinc-PPIX; ALAS2 gene testing confirmsIron supplementation responseMixed or unpredictable; may transiently worsen PPIX levels and symptomsOften beneficial; reduction in PPIX seen in several cohorts; generally, better toleratedOther medical therapiesAvoidance of triggers; bile flow optimization (UDCA); cholestyramine, or colestipol to interrupt enterohepatic PPIX cyclingSimilar supportive approach; may respond better to iron repletion due to intact ferrochelataseAdvanced/Rescue therapiesPlasmapheresis, red-cell exchange, IV hemin, or liver transplantation for severe hepatopathySame advanced options as EPP when liver disease developsEmerging therapiesAfamelanotide (photosensitivity relief; possible hepatoprotection), bitopertin, ABCG2 inhibitorsSame emerging agents; bitopertin may be particularly relevant due to high erythroid PPIX productionPrognosisGenerally stable but complicated by episodic phototoxicity; small subset progresses to severe liver diseaseSimilar phototoxic course; hepatopathy risk comparable but may respond more favorably to iron Table 1Comparison of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Clinical features and management.DomainEPPXLPGenetic basisAutosomal recessive or biallelic FECH deficiencyX-linked gain-of-function variants in ALAS2PathophysiologyReduced ferrochelatase activity → impaired insertion of iron into PPIX → accumulation of free PPIXIncreased ALAS2 activity → overproduction of PPIX despite normal ferrochelatase functionAge of onsetUsually childhoodChildhood or adulthood; sometimes later recognitionPhotosensitivityCommon; immediate burning, erythema, and pain after minimal sunlight exposureClinically similar to EPP; often indistinguishable based on symptoms aloneHematologic profileIron deficiency frequent; ferritin often low or low-normalIron deficiency also common; may be more pronouncedLiver involvementRisk of hepatic PPIX deposition leading to cholestasis and hepatopathy; may progress to liver failure in severe casesAt risk for hepatopathy; severity can mirror EPP, but some cases may progress more rapidly due to higher PPIX levelsDiagnostic cluesElevated erythrocyte PPIX with high free-to‑zinc PPIX ratio; FECH gene testing confirmsElevated erythrocyte PPIX with proportionally higher zinc-PPIX; ALAS2 gene testing confirmsIron supplementation responseMixed or unpredictable; may transiently worsen PPIX levels and symptomsOften beneficial; reduction in PPIX seen in several cohorts; generally, better toleratedOther medical therapiesAvoidance of triggers; bile flow optimization (UDCA); cholestyramine, or colestipol to interrupt enterohepatic PPIX cyclingSimilar supportive approach; may respond better to iron repletion due to intact ferrochelataseAdvanced/Rescue therapiesPlasmapheresis, red-cell exchange, IV hemin, or liver transplantation for severe hepatopathySame advanced options as EPP when liver disease developsEmerging therapiesAfamelanotide (photosensitivity relief; possible hepatoprotection), bitopertin, ABCG2 inhibitorsSame emerging agents; bitopertin may be particularly relevant due to high erythroid PPIX productionPrognosisGenerally stable but complicated by episodic phototoxicity; small subset progresses to severe liver diseaseSimilar phototoxic course; hepatopathy risk comparable but may respond more favorably to iron Comparison of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Clinical features and management. Case presentation A 64-year-old Caucasian male patient with a history of EPP and LT for decompensated cirrhosis due to protoporphyric hepatopathy and possible alcohol-related liver disease presented to our clinic in September 2021 with progressively worsening liver chemistries. He was initially diagnosed with EPP at age 20 based on biochemical testing and had not previously undergone genetic testing. He maintained a good quality of life with minimal photosensitivity until relocating to Florida in 2017 at age 60, when he developed new-onset ascites and fatigue with imaging, confirming decompensated cirrhosis with splenomegaly. He reported consuming 1–2 glasses of wine daily, denied heavier alcohol use, and discontinued alcohol following this diagnosis. Despite treatment with ursodeoxycholic acid, his labs worsened, with total bilirubin 5.7–9.8 mg/dL, aspartate aminotransferase (AST) 41–203 IU/L, alanine aminotransferase (ALT) 27–122 IU/L, alkaline phosphatase (ALP) 83–282 IU/L, albumin 2.7–5.0 g/dL, sodium 123–137 mmol/L, hemoglobin 6.7–10.7 g/dL, platelets 18–80 × 103/μL, and INR 1.4–2.2 (Fig. 1A & B). His erythrocyte protoporphyrin level in October 2018 measured 3242 μg/dL (reference interval < 80 μg/dL). He ultimately underwent LT (CMV D−/R−) in May 2019 with uncomplicated peri- and post-operative courses and gradual improvement in AST (14–29 IU/L), ALT (11–41 IU/L), ALP (79–144 IU/L), and hemoglobin (12–13 g/dL) (Figs. 1A & B). Notably, his photosensitivity completely resolved following transplantation. His immunosuppressive regimen included tacrolimus with mycophenolate mofetil, later transitioned to mycophenolic acid, with documented adherence throughout. Approximately 9 months post-transplant, in April 2020, photosensitivity recurred, prompting discussion of hematopoietic stem cell transplantation, which was ultimately deferred because of high anticipated complication risk. By December 2020, liver chemistries again became abnormal without clear precipitating factors, with AST 58–68 IU/L and ALT 102–114 IU/L while his ALP remained within normal limits (Fig. 1A). His photosensitivity concurrently worsened. A liver biopsy in January 2021 revealed minimal portal inflammation with cholestasis, stage 2/4 fibrosis, and no evidence of rejection.Fig. 1Trends in pertinent laboratory values before and after liver transplantation. (A) serial liver biochemistry and (B) hematologic values from July 2018 to August 2025. (C) Erythrocyte protoporphyrin levels before and after liver transplantation, recurrence of hepatopathy, and response to iron supplementation from October 2018 to April 2024. Vertical dotted lines denote major clinical or therapeutic events. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Fe, iron; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; TIBC, total iron-binding capacity; Zn, zinc.Fig. 1 Trends in pertinent laboratory values before and after liver transplantation. (A) serial liver biochemistry and (B) hematologic values from July 2018 to August 2025. (C) Erythrocyte protoporphyrin levels before and after liver transplantation, recurrence of hepatopathy, and response to iron supplementation from October 2018 to April 2024. Vertical dotted lines denote major clinical or therapeutic events. Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; Fe, iron; Hb, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; TIBC, total iron-binding capacity; Zn, zinc. He was subsequently referred to our institution in September 2021. As porphyrin deposition within the biliary canaliculi and portal macrophages can mimic cholestasis histologically, we repeated the liver biopsy in October 2021. This confirmed marked protoporphyrin deposition with a characteristic Maltese cross appearance under polarized light microscopy, stage 2/4 fibrosis, and no signs of rejection. Erythrocyte protoporphyrin levels were markedly elevated to 4368 μg/dL, composed predominantly of metal-free protoporphyrin (95%) with a minor zinc protoporphyrin fraction (5%) (Fig. 1C). Despite trials of ursodeoxycholic acid, cholestyramine, gabapentin, beta-carotene, vitamin E, cimetidine, and one intravenous hemin infusion, his liver chemistries and photosensitivity continued to worsen (Fig. 1A). In the absence of biopsy evidence of rejection, mycophenolic acid was temporarily discontinued between December 2021 and April 2022 as a diagnostic trial and restarted after no biochemical improvement was observed. His case was reviewed by the Porphyrias Consortium in July 2022, when his erythrocyte protoporphyrins levels had risen to 5561 μg/dL (85% metal-free protoporphyrin and 15% zinc protoporphyrin) (Fig. 1C). Consortium members recommended genetic testing, re-evaluation for bone marrow transplantation, and avoidance of afamelanotide given prior LT and persistent liver enzyme abnormalities. Clinical panel-based next-generation sequencing identified a pathogenic hemizygous ALAS2 frameshift variant, NM_000032.4:c.1706_1709del (p.Glu569Glyfs*24), establishing the diagnosis of X-linked protoporphyria (XLP) rather than EPP. Complete blood count and iron studies were consistent with iron deficiency anemia (hemoglobin 11.7 g/dL, MCV 71 fL, ferritin 17 ng/mL, percent transferrin saturation 6.7%). Because XLP was expected to respond to iron repletion, oral ferrous sulfate 325 mg daily was started and within weeks of starting oral iron, he reported substantial improvement in energy and photosensitivity. Coinciding with iron repletion, his erythrocyte protoporphyrin level decreased from 5561 to 1940 μg/dL (54% metal-free protoporphyrin and 46% zinc protoporphyrin), and his AST and ALT quickly normalized (Fig. 1B and C). Vibration-controlled transient elastography performed during this period demonstrated a liver stiffness of 8.1 kPa (F2), consistent with mild fibrosis. As of August 2025, his liver enzymes have normalized and photosensitivity has not recurred; he remains off ursodeoxycholic acid and continues on oral iron supplementation, and has stable graft function on tacrolimus extended-release 2 mg daily. He has resumed unrestricted prolonged outdoor activities, including fishing and golfing. Discussion Recurrent protoporphyric hepatopathy after liver transplantation occurs commonly, with 65–69% of patients developing disease recurrence in the graft, and 43% experiencing recurrence within the first year post-transplant [17], [18], [19]. Although treatment options for protoporphyric hepatopathy are limited, recent expert guidelines provide a framework for management, emphasizing supportive therapies, monitoring strategies, and consideration of advanced interventions, including hematopoietic stem cell transplantation (Table 1) [3], [5], [8], [9], [10]. As expected, intravenous hemin, which acts primarily through negative feedback inhibition of hepatic ALAS1 and is most useful in acute hepatic porphyria attacks, did not improve this patient's liver chemistries or photosensitivity, consistent with the distinct pathophysiology of XLP, which is driven by erythroid ALAS2 overactivity rather than hepatic heme synthesis. This case underscores the critical importance of distinguishing XLP from EPP, as this differentiation directly impacts therapeutic decision-making. Confirmation of XLP through genetic testing, coupled with recognition of iron deficiency, provided the rationale for iron supplementation, an intervention expected to benefit patients with XLP but not EPP. Following iron repletion, the patient achieved dramatic improvement in both photosensitivity and recurrent post-liver transplant protoporphyric hepatopathy [7]. Male patients with XLP may be at particular risk for severe liver disease, with protoporphyrin levels on average twice those seen in EPP patients, further highlighting the significance of accurate diagnosis [20]. The differential response to iron supplementation between XLP and EPP is rooted in fundamental differences in their underlying pathophysiology. Under normal conditions, iron regulatory proteins 1 and 2 (IRP-1/2) post-transcriptionally regulate ALAS2 by binding to iron-responsive elements in its 5′ untranslated region, thereby repressing translation under iron-deficient conditions and permitting increased ALAS2 expression when iron is sufficient [21]. In XLP, gain-of-function mutations in ALAS2 impair this normal regulatory mechanism. When iron deficiency is superimposed in XLP, the mismatch between protoporphyrin production and iron availability is further exacerbated, leading to accumulation of toxic free protoporphyrin [22]. In contrast, EPP results from ferrochelatase deficiency itself, meaning iron repletion cannot bypass this enzymatic bottleneck and may paradoxically increase PPIX production by stimulating erythropoiesis [7], [14], [23]. Clinical studies support the hypothesis that iron repletion in XLP restores substrate availability for ferrochelatase to efficiently incorporate iron into PPIX, reducing the toxic free PPIX pool [3], [7]. Ferrochelatase is an [2Fe–2S] iron–sulfur cluster enzyme whose maturation and stability is dependent on iron availability and intact Fe—S cluster assembly machinery [24]. Therefore, it is possible that iron repletion in iron-deficient patients with XLP may provide additional benefit by directly improving ferrochelatase stability and function [24]. The etiology of this patient's iron deficiency remained unclear; prior upper and lower endoscopic evaluations were unremarkable, though they were not repeated closer to the time of diagnosis of iron deficiency anemia. In XLP, no specific target has been established for ferritin levels to minimize PPIX accumulation. We believe targeting a serum ferritin level of 30–100 ng/mL in the absence of chronic inflammatory conditions (where higher goals may be appropriate) is reasonable to avoid iron-restricted erythropoiesis in XLP [25], [26]. This approach aims to ensure adequate substrate availability for ferrochelatase, thereby facilitating conversion of PPIX to heme and reducing accumulation of the toxic free PPIX pool responsible for both photosensitivity and hepatic injury. Moving forward, ongoing monitoring of ferritin and erythrocyte protoporphyrin levels, as well as liver function will be essential to assess treatment response and to detect any recurrence of hepatopathy [7], [27]. Genetic testing proved essential in this case, as the initial erythrocyte protoporphyrin fractionation was misleading. The patient's zinc protoporphyrin fraction of only 5–15% suggested EPP rather than XLP. Typically, in EPP, zinc protoporphyrin constitutes approximately 5% of total protoporphyrin, whereas in XLP, it ranges from 20 to 40%, though considerable overlap can occur. This discordance highlights that protoporphyrin fractionation alone cannot reliably distinguish between these conditions, and definitive genetic testing is necessary for accurate diagnosis and appropriate therapeutic planning [20], [28]. Several investigational therapies for EPP and XLP hold promise but remain in development. Bitopertin, an inhibitor of the glycine transporter, GLYT1, has demonstrated potential to lower PPIX production in erythroblasts and plasma [29]. Similarly, oral ABCG2 inhibitors targeting the ATP-binding cassette G2 transporter have shown potential in reducing systemic PPIX levels and mitigating both phototoxic responses and hepatic injury [30], [31]. Afamelanotide, an α-melanocyte-stimulating hormone analog primarily developed to improve photosensitivity, has shown dose-dependent hepatoprotective effects in some, but not all, clinical studies; however, this patient did not qualify for this medication as clinical trials excluded patients with liver transplants or pre-existing liver injury [32], [33], [34] and would not be expected to lower erythrocyte PPIX. Dersimelagon, an oral melanocortin-1 receptor agonist that similarly promotes photoprotection through increased skin eumelanin production, has shown efficacy in increasing sunlight tolerance in phase 2 and phase 3 trials enrolling patients with EPP and XLP; however, like afamelanotide, it acts on skin pigmentation rather than on PPIX production and would not be expected to independently reverse the elevated PPIX burden driving this patient's hepatopathy [35]. Dersimegalon is not commercially available in the United States. The clinical trajectory observed in this case likely reflects multiple mechanistic factors. XLP results in persistently elevated erythrocyte PPIX, which can overwhelm hepatic excretory capacity and predispose graft hepatocytes to cholestasis, bile canalicular injury, and protoporphyrin crystal deposition [3], [6], [7], [36]. Concurrent iron deficiency further limited substrate availability for ferrochelatase to efficiently incorporate iron into PPIX, thereby sustaining a large free PPIX pool. Although liver transplantation initially restored biliary clearance, which was evidenced by normal liver chemistries 1.5 years post-transplant, the graft remained vulnerable to recurrent PPIX-mediated injury because the systemic PPIX burden remained high (Fig. 1). By resolving iron deficiency and reducing PPIX levels, iron supplementation successfully mitigated the “second hit” on the graft and reversed both hepatic injury and photosensitivity [19], [27]. To our knowledge, this represents the first report demonstrating clear improvement in liver dysfunction with iron repletion in an adult with XLP. Conclusion In summary, this case importantly demonstrates that iron repletion can serve as a disease-modifying therapy in XLP, even after liver transplantation. Although this patient underwent myriad therapies, such as intensifying immunosuppression and trialing different medications like ursodiol, vitamin E, cimetidine, and cholestyramine, none addressed the underlying problem, prompting consideration of hematopoietic stem cell transplantation. This case underscores the importance of prompt genetic confirmation in any patient with presumed porphyria, even when the zinc protoporphyrin fraction suggests one diagnosis over another. It also highlights the need for routine assessment of iron status in XLP and the early consideration of iron supplementation, both as a preventive measure, ideally as soon as XLP with iron deficiency is confirmed and before the onset of overt liver disease, and as a therapeutic intervention in patients with established XLP-associated hepatopathy, including in the post-transplant setting. Prompt iron repletion may help avert progression to liver failure and the need for transplantation, as suggested by this patient's marked improvement in liver function following iron repletion even after transplant. Earlier recognition of XLP and iron deficiency may have allowed this patient to achieve clinical and biochemical remission sooner, and more importantly, regain his quality of life through a simple, low-risk intervention. CRediT authorship contribution statement Christopher D. Ma: Visualization, Data curation, Writing – original draft. Giuliana Arevalo: Visualization, Data curation, Writing – original draft. Cynthia Levy: Supervision, Conceptualization, Writing – review & editing. Siobán B. Keel: Writing – review & editing. Ethics declaration Informed consent and patient details Written informed consent to take part in the study and to publish the article has been obtained from all participants or their legal representatives. The privacy rights of participants have been observed. Studies in human This study was performed in compliance with relevant laws, regulatory frameworks and guidelines where the research took place. Ethics committee approval was not required under relevant laws and institutional guidelines. IRB review not required for case report. Case reports This research follows the CARE guidelines and the CARE checklist. Declaration of competing interest The authors declare no conflicts of interest regarding the publication of this report.